ACT Program for ZOLINZA® (vorinostat): Healthcare reimbursement information

Explore these resources
to find support during your treatment.

Learn how the ACT program can help you access treatment.

Learning About ZOLINZA® (vorinostat) CTCL treatment Understanding CTCL Care-Partner corner Talking with your treatment team Resources Patient Information Physician Prescribing Information Information for health care professionals

To report side effects, call 800-FDA-1088.

ACT Program Brochure

View the ACT Program Brochure in PDF Format

[PDF: 493 KB, 18 pages]

To view PDF documents, you must
have Adobe Reader installed on your computer.

ZOLINZA is a registered trademark of Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.
This site is intended for residents of the United States, its territories, and Puerto Rico.
20850619(7)-01/10-ZOL